[Therapeutic effect of sulfobenzyl-penicillin (SB-PC) on the concentration of SB-PC in human bile (author's transl)].
Sulfobenzyl-penicillin (SB-PC) is currently being investigated for use in man. The purpose of this study was to evaluate effect of SB-PC on Salmonella typhosa and biliary excretion of SB-PC in disease of the biliary tract. 1) Clinically, typhoid carriers without cholelithiasis were initiated with 4.0 g/day of SB-PC. Stool and bile became negative for Salmonella typhosa 14 days after initial treatment. 2) In typhoid carriers with cholelithiasis, Salmonella typhosa were not isolated from bile, wall of the gallbladder and surface of gallstone, but were isolated from nuclei of gallstones. The treatment of typhoid carriers with cholelithiasis may belong to a most difficult problem. 3) Biliary excretion of SB-PC in the patient given a single dose of 2.0 g/day im. was markedly dependent on characteristics of the patient, situation of external drainage and volume of bile excretion. High concentration in bile in some patient was 298 mug/ml at 3 hours after administration. 4) In intravenous administration of single dose of 6.0 g. maximum concentration in bile was about 2,000 mug/ml at 2 hours after administration and bactericidal concentration was obtained for resistant bacteria (Pseudomonas, Proteus, etc.) in biliary infection. 5) As side effects, pain and redness were infrequent after im. administration. Toxicity was not experienced in the patients injected intravenously.
D000368:Aged; D001646:Bile / Q000378:metabolism*; D002353:Carrier State / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010400:Penicillin G / Q000031:analogs & derivatives*; D013408:Sulbenicillin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D014435:Typhoid Fever / Q000188:drug therapy*
D013408:Sulbenicillin; D010400:Penicillin G